Skip to Content
Merck
CN

Key Documents

View All Documentation

SML2134

Finafloxacin

≥95% (HPLC)

Synonym(s):

8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C20H19FN4O4
CAS Number:
209342-40-5
Molecular Weight:
398.39
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥95% (HPLC)
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

Fc1cc2c([n](cc([c]2=O)C(=O)O)C5CC5)c(c1N3C[C@@H]4NCCO[C@H]4C3)C#N

InChI

1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1

InChI key

FYMHQCNFKNMJAV-HOTGVXAUSA-N

Biochem/physiol Actions

Finafloxacin is a fluoroquinolone antibiotic approved by the FDA in 2014 for treating swimmer′s ear. Its mechanism of action involves the inhibition of bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV
Fluoroquinolone antibiotic

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 1B - Repr. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000230822
0000230822
0000127619
0000041846
0000041845

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance.
Linnell B Randall et al.
The Journal of antimicrobial chemotherapy, 72(4), 1258-1260 (2017-01-01)
Will Stubbings et al.
Antimicrobial agents and chemotherapy, 55(9), 4394-4397 (2011-06-29)
Finafloxacin is a novel fluoroquinolone that exhibits enhanced antibacterial activity under acidic conditions. The aim of this study was to define the in vitro pH-activity relationship. Finafloxacin exhibited optimal antibacterial activity between pH 5.0 and 6.0 at which MICs were
Jung Won Lee et al.
Antimicrobial agents and chemotherapy, 59(12), 7629-7636 (2015-09-30)
Finafloxacin is a novel fluoroquinolone with improved antimicrobial efficacy, especially in an acidic environment. The efficacy of finafloxacin for the inhibition of Helicobacter pylori infection was compared with the efficacies of levofloxacin and moxifloxacin at neutral and acidic pH. The

Global Trade Item Number

SKUGTIN
SML2134-50MG04061835302819
SML2134-10MG04061835302802